Yifan Pharmaceutical Third Quarter 2024 Earnings: EPS: CN¥0.09 (vs CN¥0.03 in 3Q 2023)
Yifan Pharmaceutical (SZSE:002019) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥1.23b (up 24% from 3Q 2023).
- Net income: CN¥113.2m (up 196% from 3Q 2023).
- Profit margin: 9.2% (up from 3.9% in 3Q 2023).
- EPS: CN¥0.09 (up from CN¥0.03 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Yifan Pharmaceutical Earnings Insights
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are up 3.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Yifan Pharmaceutical that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002019
Yifan Pharmaceutical
Engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally.
Reasonable growth potential with adequate balance sheet.
